当日、回線システムに不具合があった場合など、延期、または中止することがありま

す。本オンラインセミナーは、講演者からの情報提供の機会を供するものであり、主

催者、共催者が、それぞれの組織、情報について、妥当性や正確性などを保証するも

のではありません。主催者は、個人情報について適切に取り扱います。主催者からの

貿易投資情報の提供に利用します。オンラインセミナーにお申し込みされた場合は、

参加者が自らの意志で個人情報提供、利用目的に同意されたものとみなします。

オーストラリア再生医療 アカデミア研究開発 オンラインセミナー

21 APRIL 2017

日本との協業が広がるオーストラリアの再生医療 優れた大学・研究機関が現地から最新情報を提供 再生医療においても、オーストラリアのイノベーションが世界で評価されています。他家iPS 細胞由来間葉系幹細胞を用いた治験を英国で開始するオーストラリアの Cynata 社に富士フィルムが出資したり(関連記事)、他家間葉系幹細胞を用いた変形性膝関節症の治療薬を開発する Regeneus 社が旭硝子とコラボレーションを開始する(関連記事)など、日本との協業例が多く見られるようになりました。 更なる日豪の協業を促すため、オーストラリア貿易投資促進庁 Austrade は、再生医療イノベーションフォーラム(FIRM)とともに、下記のようにオンラインセミナーを開催します。今回はアカデミアに焦点をあて、オーストラリアの基礎研究や臨床研究に優れた大学、研究機関から研究者 3 名(Professor Christine Wells、Professor Bernie Tuch、Professor Dietmar Hutmacher)を講演者として迎え、現地より最新情報をライブ発信します。 日時： 2017 年 4 月 21 日(金) 午後 2 時から午後 3 時 30 分まで 形式： オンラインセミナー。ご自身のパソコン、スマートフォンなどから、指定リンクに アクセスすることで参加できます。 主催： オーストラリア貿易投資促進庁 Austrade 共催： 一般社団法人再生医療イノベーションフォーラム(FIRM) 言語： 英語 （スライドに日本語訳の挿入） 費用： 無料 対象： FIRM の会員の皆様をはじめ、再生医療に関わる全ての方々 参加お申し込み・登録方法 1) まず、Web フォーム www.tinyurl.com/mtvf5zn (または右 Q コード)にてお申

し込みください。(この時点で登録は完了していません) 2) 次に、参加/登録方法マニュアル、および登録フォームへのリンクが、お申し込み

いただいた方のＥメイルアドレスに送られます。フォームに入力いただくと、登録が完了します。当日は、マニュアルを参考にご参加いただきます。

最大の参加者数： 300 名。到達した時点で締め切ります。お早めにお申し込みください。 個別に登録が必要： 同じ企業から複数の方が参加される場合でも、個別にお申し込みください。 個々に発行されるアクセスリンクは、他の方と共有することができません。

お問い合わせ： 在大阪オーストラリア総領事館 吉本 Tel: 06-6941-9383 Email: takehiro.yoshimoto@austrade.gov.au

Page 2 of 4

講演者の紹介 Stem Cells Australia: A national network of infrastructure, capacity and expertise in regenerative medicine.

Stem Cells Australia: 再生医療のインフラ、研究能力、専門性の国家ネットワーク

Stem Cells Australia is a national program funding excellence in basic and applied stem cell biology. SCA researchers work on heart disease-in-a-dish, and clinical trials of heart regeneration; blood cell development and new methods of blood mobilisation; brain repair through stem cell transplants as well as stimulation of the native brain stem cells. I will present snapshots of the work from leading researchers across Australia, with an emphasis on models of aging, and platforms for screening kidney, gut and liver disease.

Stem Cells Australia (SCA)は、卓越した細胞生物学の基礎、および応用研究への資金提供を伴った国家プログラムです。SCA

の研究者達は、心臓疾患のシャーレ内再現、心臓再生の臨床試験、血液細胞の発生および血流変化の新方法、幹細胞移植や体

内脳幹細胞の刺激による脳修復などに取り組んでいます。老化モデルや、腎臓、腸および肝疾患のスクリーニングのためのプ

ラットフォームに重点を置いて、オーストラリアの代表的な研究者の取り組みをご紹介します。

Professor Christine Wells Director, Centre for Stem Cell Systems, University of Melbourne, Australia Deputy Program Lead, Stem Cells Australia ARC Future Fellow Chair, Stem Cell Systems, University of Melbourne Honorary Fellow, Walter and Eliza Hall Institute Emeritus Professor, The University of Queensland, Australia

Professor Christine Wells is the sounding Director of the University of Melbourne Centre for Stem Cell Systems. She is the deputy program leader for Stem Cells Australia, an ARC funded $21M special research initiative to bring together leading Australian stem cell scientists. Christine is a genome biologist interested in tissue injury and repair. She

leads a program of research in biological data integration and visualization for the stem cell community, including method development leading to gene discovery and characterization of stem cell subsets and innate immune cells.

Professor Wells has published over 92 scientific journal articles, in the leading scientific literature, including landmark studies in mapping gene architecture and function. She has developed several open source software programs, including the Stemformatics.org stem cell collaboration resource, which has a global audience, and which hosts the largest compendium of curated stem cell data. This resource is used to generate definitive molecular signatures of stem cell subsets and their differentiated progeny, including accurate classification of MSC from different tissues. Over the last 16 years, Christine has worked with the Japanese genome consortium, FANTOM, led from the RIKEN Center for Life Science Technologies (CLST), Yokohama, on discovery of the genetic toolkit used by cells and tissues during development, growth, aging and disease.

Page 3 of 4

Business Opportunities in Regenerative Medicine, Sydney

シドニーの再生医療におけるビジネス機会

Professor Bernie Tuch, Director of the NSW Stem Cell Network, and with an affiliation at both The University of Sydney and Monash University will be presenting a number of regenerative medicine projects being developed by academics based at The University of Sydney. They will include a device to deliver insulin-producing stem cells as a therapy for diabetes, cardiomyocytes derived from pluripotent stem cells as a cardiac therapy, the use of dermal stem cells for hair growth and corneas derived from pluripotent stem cells as a cataract therapy. Professor Tuch, who is a translational endocrinologist, has conducted clinical trials for the treatment of diabetes previously, and it is an extension of the original trial that he will be talking about at the webinar.

NSW Stem Cell Network のディレクターであり、シドニー大学とモナッシュ大学に所属する Bernie Tuch 教授は、シドニ

ー大学を拠点とする研究者が取り組む再生医療プロジェクトを数多く発表します。糖尿病の治療のためのインスリン産生幹細

胞の送達ディバイス、心臓療法としての多能性幹細胞由来の心筋細胞、育毛のための真皮幹細胞の使用、白内障治療としての

多能性幹細胞由来の角膜などが含まれます。トランスレーショナル内分泌学者である Tuch 教授は、以前に糖尿病治療の臨床

試験を行ってきましたが、その発展についてもお話します。

Professor Bernie Tuch Director, NSW Stem Cell Network Honorary Professor, School of Medical Sciences, Discipline Physiology, The University of Sydney

Professor Bernie Tuch is Director of the NSW Stem Cell Network, an endocrinologist in private practice, and a Professor of Medicine at both The University of Sydney and Monash University. In the 1980's, Dr Tuch was in charge of the Australian group that first transplanted human fetal pancreatic tissue into people with type 1 diabetes. In 2006, he and colleagues conducted another Diabetes Therapy Trial, with insulin-producing cells

derived from human donors after their death. The cells were placed in immunoisolating microcapsules made from alginate, a product from seaweed. Around the same time, and with support from the NHMRC Embryo Licensing Committee, he and colleagues made 2 new human embryonic stem cell lines, called Endeavour-1 and Endeavour-2. These cells are being used for research purposes by a number of different groups. Their possible use in the clinic is being examined.

Page 4 of 4

Bone and Breast Tissue Engineering from Bench to Bedside

ベンチからベッドサイドまでの骨および乳房細胞工学

Today's, major reconstructive surgery may be limited by the paucity of autologous materials available and donor site morbidity. Recent advances in the development of biomaterials and tissue engineering have given the surgeon new options for restoring form and function. This talk reviews the mayor current strategies in challenging bone breast engineering applications from a translational science perspective as well as from a clinical angle. Examples of the studies using additive biomanufactured scaffolds in combination with growth factors (PRP, BMPs) and/or mesencymal stem cells in thoroughly characterized and validated preclinical animal models will be presented.

現在、主要な再建手術は、自家組織の不足、およびドナー部位の罹患によって制限され得ます。 生体材料および生体組織工

学の進歩により、外科医は形態および機能を回復するための新たな選択肢を得ました。 本講演では、トランスレーショナル

サイエンスの観点、および臨床面から、課題がある骨・乳房のエンジニアリングに適用される主要な現在の戦略を見直します。

前臨床動物モデルによって完全に特性決定され有効性が証明された研究で、付加生物製造されたスカフォードを、増殖因子

（PRP、BMP）および/または間葉系幹細胞と組み合わせて用いた例を提示します。

Professor Dietmar W. Hutmacher PhD (NUS), MBA (Henley)

QUT Chair in Regenerative Medicine, Institute of Health and Biomedical Innovation, Queensland University of Technology

Professor Dietmar W. Hutmacher is Professor and Chair of Regenerative Medicine at the Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology, where he directs the Centre of Regenerative Medicine and the ARC Centre in Additive Biomanufacturing. Both centres are composed of a

multidisciplinary teams including engineers, cell biologists, polymer chemists, clinicians, and veterinary surgeons. He is a biomedical engineer who is one of very few academics in the field of biomaterials/tissue engineering to have taken a research programme from fundamental research through to clinical application utilising research in-vitro, in-vivo, preclinical large animal studies and clinical trials. Over the last decade Professor Hutmacher has gained a worldwide reputation in the field of tissue engineering/regenerative medicine, and his track record illustrates successful mastery of a major challenge in an interdisciplinary field: the ability to transcend traditional disciplinary boundaries, and initiate and nurture research and educational programs across different disciplines. His success has been achieved through a concerted and integrated leadership effort including contributions from colleagues in engineering (tissue engineering, biomaterials science, computational modelling, chemistry, nanotechnology), the life science disciplines (molecular, cell and developmental biology, medicine, stem cell research, genomics, proteomics, bioinformatics), and applied clinical research (orthopaedics, plastic surgery, radiology, etc.). He is a biomedical engineer who is one of very few academics in the field of biomaterials/tissue engineering who has embraced a holistic approach and has taken a research programme from fundamental research through to clinical application utilising research in-vitro, in-vivo, preclinical large animal studies and clinical trials. As a reflection of his pioneering ethos, his visionary research efforts have resulted in traditional scientific/academic outputs as well as pivotal commercialisation outcomes. He has pioneered a number of scaffolding approaches to engineer bone, cartilage, skin and breast tissue, with his work on scaffold design and fabrication via 3D printing creating new research paradigms, making this process one of the most commonly used in the field today. As a result of this unique combination of expertise and experience, he is one of the few academics to take a holistic bone-engineering concept from fundamental research to clinical application. He has secured FDA and CE Mark approval for a patient-specific bone repair implant, setting a new trend in the areas of reconstructive surgery and more broadly personalised medicine – more than 400 patients have been treated to date with this technology. This technology has been commercialised by Osteopore International. Most recently Professor Hutmacher has established a spin-off company Bella Seno GmbH in Germany and a Australian based company Biodesign Fabrication Solutions (BDS) which aim to start clinical trails and ultimately commercialise the patented and newly developed breast tissue-engineering concept based on biomanufacturing principles.

予告なく講演者、内容を変更することがあります。